-transparent.png){kind=logo}
The effects of human leukocyte interferon (HulFN-alpha) and fibroblast interferon (HulFN-beta) on cell growth and induction of antigens related to Epstein-Barr virus (EBV) in a nasopharyngeal carcinoma hybrid cell line (NPC-KT) were studied. HulFN-alpha showed little antiproliferative and anti-EBV effect on NPC-KT cells. On the other hand, HulFN-beta showed modest antiproliferative effect on NPC-KT cells; the effect was dependent on time and HulFN-beta concentration. HulFN-beta alone was ineffective in inhibiting EBV-related antigens, but NPC-KT cells treated for more than 1 week with HulFN-beta inhibited the action of the chemical inducer of EBV, n-butyric acid, and the appearance of EBV-induced early antigen and EB viral capsid antigen was inhibited more than 50% compared with NPC-KT cells treated with n-butyric acid alone.
T Takimoto, and
S Ishikawa, and
R Umeda, and
H Ogura, and
M Hatano
August 1989,
Journal of virology,
T Takimoto, and
S Ishikawa, and
R Umeda, and
H Ogura, and
M Hatano
January 1984,
American journal of otolaryngology,
T Takimoto, and
S Ishikawa, and
R Umeda, and
H Ogura, and
M Hatano
January 1985,
Auris, nasus, larynx,
T Takimoto, and
S Ishikawa, and
R Umeda, and
H Ogura, and
M Hatano
November 1984,
Gan,
T Takimoto, and
S Ishikawa, and
R Umeda, and
H Ogura, and
M Hatano
May 1987,
Archives of otolaryngology--head & neck surgery,
T Takimoto, and
S Ishikawa, and
R Umeda, and
H Ogura, and
M Hatano
January 1984,
ORL; journal for oto-rhino-laryngology and its related specialties,
T Takimoto, and
S Ishikawa, and
R Umeda, and
H Ogura, and
M Hatano
March 2009,
Microbes and infection,
T Takimoto, and
S Ishikawa, and
R Umeda, and
H Ogura, and
M Hatano
March 1976,
Proceedings of the National Academy of Sciences of the United States of America,
T Takimoto, and
S Ishikawa, and
R Umeda, and
H Ogura, and
M Hatano
August 1978,
Archives of otolaryngology (Chicago, Ill. : 1960),
T Takimoto, and
S Ishikawa, and
R Umeda, and
H Ogura, and
M Hatano
July 1983,
Journal of the National Cancer Institute,
